SCHEMBL19630358

SCHEMBL19630358

N#Cc1cnc(N)cc1OC1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TRPC6 Q9Y210 2/20 0.40
FGFR4 P22455 2/20 0.38
XDH P47989 1/20 0.38
MCHR1 Q99705 2/20 0.38
TBK1 Q9UHD2 2/20 0.37
MAP4K3 Q8IVH8 1/20 0.36
PDE5A O76074 1/20 0.35
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE1C Q14123 1/20 0.35
IKBKE Q14164 1/20 0.35
LNPEP Q9UIQ6 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29596842 1.00 TRPC6 (0.40) TRPC6FGFR4XDHMCHR1TBK1
SCHEMBL19866731 0.97 TRPC6 (0.38) TRPC6FGFR4XDHMCHR1TBK1
SCHEMBL21011635 0.94 TBK1 (0.39) TRPC6TBK1IKBKE
SCHEMBL22151843 0.87 PRKCQ (0.36) TRPC6FGFR4TBK1IKBKE
SCHEMBL16668090 0.87 TBK1 (0.48) TBK1IKBKE
SCHEMBL16667831 0.85 ABL1 (0.46) FGFR4TBK1IKBKE
SCHEMBL16668393 0.82 FGFR4 (0.43) FGFR4TBK1IKBKE
SCHEMBL16667999 0.82 FGFR4 (0.43) FGFR4TBK1IKBKE
SCHEMBL16667784 0.82 FGFR4 (0.43) FGFR4TBK1IKBKE
SCHEMBL16667991 0.81 IKBKE (0.44) FGFR4TBK1IKBKE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3663285-B1 FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-01-24 EP disclosed
EP-3663285-B1 FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2024-01-24 EP disclosed
US-11312701-B2 Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof ABBISKO THERAPEUTICS CO., LTD (CN) 2022-04-26 US disclosed
US-20210130323-A1 FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-05-06 US disclosed
EP-3663285-A1 FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2020-06-10 EP disclosed
EP-3444250-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2019-02-20 EP disclosed
WO-2017198149-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF 江苏豪森药业集团有限公司 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312701-B2 Formylpyridine derivative having FGFR4 inhibitory activity, preparation method therefor and use thereof FGFR4, FGFR1, FGFR2 TRPC6 3518/4885FGFR4 1/4885XDH 2494/4885
US-20210130323-A1 FORMYLPYRIDINE DERIVATIVE HAVING FGFR4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR4, FGFR1, FGFR2 TRPC6 3518/4885FGFR4 1/4885XDH 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.